Epix completes study enrollment
Contrast media developer Epix Medical has completed enrollment in the second of two phase III trials designed to detect peripheral vascular disease in the aortoiliac arteries using the company¹s new blood pool MR agent, MS-325. The company expects to
Contrast media developer Epix Medical has completed enrollment in the second of two phase III trials designed to detect peripheral vascular disease in the aortoiliac arteries using the company¹s new blood pool MR agent, MS-325. The company expects to complete a review of the data and release results in spring 2003. Positive study results from the first trial were reported last March at the annual American College of Cardiology meeting. Epix continues to enroll patients in the remaining two phase III clinical trials aimed at detecting peripheral vascular disease in the renal and pedal arteries. Enrollment in these trials should be completed in the first quarter of 2003. Epix plans to file a new drug application with the FDA for MS-325 approximately six months after enrollment is completed.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
